NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM724287 Query DataSets for GSM724287
Status Public on Aug 19, 2012
Title underPatient8-2
Sample type RNA
 
Channel 1
Source name non tumor lesion of liver biopsy, 8weeks after starting peretinoin administration
Organism Homo sapiens
Characteristics patient: 8-2
tissue: non tumor lesion of liver biopsy
agent: peretinoin
time: 8 weeks
agent dose: 600mg
clincal outcome: nonRecurrence of HCC
Treatment protocol Peretinoin, a member of the acyclic retinoid family, is expected to be an effective chemo preventive drug for HCC.The patients had undergone curative surgical resection or radiofrequency ablation (RFA). They received 300 mg/day or 600 mg/day of peretinoin for 8 weeks and were followed up for 88 weeks with 600 mg/day of peretinoin. Hepatic gene expression profiling obtained from non tumor lesion of these patients prior to administering peretinoin and 8 weeks after starting peretinoin treatment
Extracted molecule total RNA
Extraction protocol Total RNA was isolated from liver biopsy samples using an RNA extraction kit (Micro RNA Extraction Kit, Stratagene, La Jolla, CA, USA). Aliquots of total RNA (5 ug) were subjected to amplification with antisense RNA (aRNA) using a Message AmpTM aRNA kit (Ambion, Austin, TX, USA) as recommended by the manufacturer
Label Cy5
Label protocol As a reference for each microarray analysis, aRNA samples prepared from the normal liver tissue from one of the patients were used. Test RNA samples fluorescently labeled with cyanine (Cy) 5 and reference RNA labeled with Cy3 were used for microarray hybridization
 
Channel 2
Source name normal liver sample from a patient [reference]
Organism Homo sapiens
Characteristics tissue: normal liver
Treatment protocol Peretinoin, a member of the acyclic retinoid family, is expected to be an effective chemo preventive drug for HCC.The patients had undergone curative surgical resection or radiofrequency ablation (RFA). They received 300 mg/day or 600 mg/day of peretinoin for 8 weeks and were followed up for 88 weeks with 600 mg/day of peretinoin. Hepatic gene expression profiling obtained from non tumor lesion of these patients prior to administering peretinoin and 8 weeks after starting peretinoin treatment
Extracted molecule total RNA
Extraction protocol Total RNA was isolated from liver biopsy samples using an RNA extraction kit (Micro RNA Extraction Kit, Stratagene, La Jolla, CA, USA). Aliquots of total RNA (5 ug) were subjected to amplification with antisense RNA (aRNA) using a Message AmpTM aRNA kit (Ambion, Austin, TX, USA) as recommended by the manufacturer
Label Cy3
Label protocol As a reference for each microarray analysis, aRNA samples prepared from the normal liver tissue from one of the patients were used. Test RNA samples fluorescently labeled with cyanine (Cy) 5 and reference RNA labeled with Cy3 were used for microarray hybridization
 
 
Hybridization protocol Reference papers; Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Hepatology. 2006 Nov;44(5):1122-38, Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Gastroenterology. 2001 Mar;120(4):955-66.
Scan protocol Quantitative assessment of the signals on the slides was carried out by scanning on a ScanArray 5000 (General Scanning, Watertown, MA, USA) followed by image analysis using GenePix Pro 4.1(Axon Instruments, Union City, CA, USA)
Description 600mgnonRecurrence
Data processing Because the levels of expression of some housekeeping genes were also changed, especially in advanced stages of liver disease, for the normalization of data we averaged intensities of all spots obtained with Cy3 and Cy5 in each of the 16 rectangles and adjusted intensity of each corrected DNA spot as the average intensity ratio Cy5/Cy3 = 1.0. This global normalization of intensity provided smaller variance of CyS/Cy3 ratio and almost equivalent results to normalization using the housekeeping genes.
Reference papers; Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Hepatology. 2006 Nov;44(5):1122-38, Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Gastroenterology. 2001 Mar;120(4):955-66.
 
Submission date May 15, 2011
Last update date Aug 19, 2012
Contact name Masao Honda
E-mail(s) mhondag@gmail.com
Phone 0762652243
Organization name Kanazawa University
Department Gastroenterology
Street address Takara-Machi 13-1
City Kanazawa
ZIP/Postal code 920-8641
Country Japan
 
Platform ID GPL13536
Series (1)
GSE29302 Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development

Data table header descriptions
ID_REF
VALUE log2 of PRE_VALUE; normalized log2 ratio (Cy5/Cy3) representing test/reference
PRE_VALUE normalized ratio (Cy5/Cy3) representing test/reference

Data table
ID_REF VALUE PRE_VALUE
1001 0.4144 1.332707608
1002 0.2624 1.199436876
1003 0.3309 1.25777262
1004 0.5095 1.423560269
1005 -0.6161 0.652426203
1006 -0.2413 0.845998974
1007 0.8746 1.833535442
1008 -0.8838 0.541924864
1009 0.0434 1.030567903
1010 -0.7473 0.595697093
1011 -0.8617 0.550292559
1012 0.2364 1.178019534
1013 0.1980 1.147118657
1014 0.1989 1.147858557
1015 0.0504 1.03554792
1016 0.2154 1.161017976
1017 0.4370 1.353830821
1018 0.1328 1.09638959
1019 0.6591 1.579064636
1020 0.1017 1.073059739

Total number of rows: 9643

Table truncated, full table size 228 Kbytes.




Supplementary file Size Download File type/resource
GSM724287_104hn2.gpr.gz 938.4 Kb (ftp)(http) GPR
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap